Professor Jane Armitage
Websites
-
University of Cambridge
Chair of INTERVAL Trial Steering Committee
-
University of Cambridge
Chair of RITARAZEM Trial Steering Committee
-
University of Cambridge
Independent Member of AdDIT Trial Steering Committee
-
University of Kelaniya
Clinical Trials Unit Scientific Advisory Board
Jane Armitage
FRCP, FFPH
Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Jane Armitage is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine. In addition, she is Director of Training and Career Development for the Nuffield Department of Population Health.
She joined the Clinical Trial Service Unit, now part of NDPH, in 1990 having qualified in clinical medicine in 1979. She worked in a variety of specialties over several years with particular experience in respiratory medicine, geriatrics and diabetes. Since joining CTSU she has co-ordinated and been chief investigator for a series of large-scale randomised clinical trials in cardiovascular disease including the 20,000 participant MRC/BHF Heart Protection Study, the 12,000 patient SEARCH and 25,000 HPS2-THRIVE study, which are trials of lipid modification in people with or at risk of vascular disease. In addition she is Chief Investigator for the BHF-supported ASCEND trial of aspirin and fish oils involving 15,000 people diabetes. She collaborates with other epidemiologists and statisticians in NDPH on a variety of genetic and other risk factor studies based on the trial cohorts. She also continues a clinical role in the Lipid Clinic at the Oxford University Hospital NHS Trust and has a particular interest in the safety of statins. Her main research interests are in lipids and the epidemiology of cardiovascular and other chronic diseases including osteoporosis.
Key publications
-
Effects of extended-release niacin with laropiprant in high-risk patients.
Journal article
HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212
-
Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
Journal article
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), JAMA, 303, 2486 - 2494
-
The safety of statins in clinical practice.
Journal article
Armitage J., (2007), Lancet, 370, 1781 - 1790
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Journal article
Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22
Recent publications
-
Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.
Journal article
Hammami I. et al, (2025), Heart
-
Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial.
Journal article
Sammons EL. et al, (2024), BMC Ophthalmol, 24
-
Design, recruitment and baseline characteristics of the LENS trial.
Journal article
LENS Collaborative Group None., (2024), Diabet Med, 41
-
Learning implementation of a guideline-based decision support system to improve hypertension management in primary care: a pragmatic cluster randomized controlled trial
Journal article
ARMITAGE J. et al, (2024), The BMJ
-
ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.
Journal article
Sammons EL. et al, (2024), Ophthalmology, 131, 526 - 533